Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature.

Abrouk M, Gandy J, Nakamura M, Lee K, Brodsky M, Singh R, Zhu H, Farahnik B, Bhutani T, Koo J.

Skin Therapy Lett. 2017 Jul;22(4):1-6. Review.

2.

Anti-IL-17 Agents for Psoriasis: A Review of Phase III Data.

Farahnik B, Beroukhim K, Nakamura M, Abrouk M, Zhu TH, Singh R, Lee K, Bhutani T, Koo J.

J Drugs Dermatol. 2016 Mar;15(3):311-6. Review.

PMID:
26954316
3.

Secukinumab: A Review in Psoriatic Arthritis.

Shirley M, Scott LJ.

Drugs. 2016 Jul;76(11):1135-45. doi: 10.1007/s40265-016-0602-3. Review.

PMID:
27299434
4.

Secukinumab for the treatment of psoriatic arthritis.

Baronaite Hansen R, Kavanaugh A.

Expert Rev Clin Immunol. 2016 Oct;12(10):1027-36. doi: 10.1080/1744666X.2016.1224658. Epub 2016 Aug 25. Review.

PMID:
27550397
5.

Anti-IL-17 phase II data for psoriasis: A review.

Brown G, Malakouti M, Wang E, Koo JY, Levin E.

J Dermatolog Treat. 2015 Feb;26(1):32-6. doi: 10.3109/09546634.2013.878448. Epub 2014 Feb 20. Review.

PMID:
24552447
6.

Secukinumab: IL-17A inhibition to treat psoriatic arthritis.

Speeckaert R, van Geel N, Lambert J, Claeys L, Delanghe JR, Speeckaert MM.

Drugs Today (Barc). 2016 Nov;52(11):607-616. doi: 10.1358/dot.2016.52.11.2526754. Review.

PMID:
28112279
7.

Secukinumab (AIN-457) for the treatment of Psoriasis.

Jaleel T, Elmets C, Weinkle A, Kassira S, Elewski B.

Expert Rev Clin Pharmacol. 2016;9(2):187-202. doi: 10.1586/17512433.2016.1129894. Review.

PMID:
26647300
8.

Secukinumab (AIN457) for the treatment of psoriasis.

López-Ferrer A, Vilarrasa E, Puig L.

Expert Rev Clin Immunol. 2015;11(11):1177-88. doi: 10.1586/1744666X.2015.1095092. Epub 2015 Oct 1. Review.

PMID:
26428036
9.

Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.

Gottlieb AB, Langley RG, Philipp S, Sigurgeirsson B, Blauvelt A, Martin R, Papavassilis C, Mpofu S.

J Drugs Dermatol. 2015 Aug;14(8):821-33.

PMID:
26267726
10.

Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.

Canavan TN, Elmets CA, Cantrell WL, Evans JM, Elewski BE.

Am J Clin Dermatol. 2016 Feb;17(1):33-47. doi: 10.1007/s40257-015-0162-4. Review.

PMID:
26649440
11.

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group.

Lancet. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28.

PMID:
26135703
12.

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.

McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, Dahmen G, Wollenhaupt J, Schulze-Koops H, Kogan J, Ma S, Schumacher MM, Bertolino AP, Hueber W, Tak PP.

Ann Rheum Dis. 2014 Feb;73(2):349-56. doi: 10.1136/annrheumdis-2012-202646. Epub 2013 Jan 29.

PMID:
23361084
13.

Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.

Imafuku S, Honma M, Okubo Y, Komine M, Ohtsuki M, Morita A, Seko N, Kawashima N, Ito S, Shima T, Nakagawa H.

J Dermatol. 2016 Sep;43(9):1011-7. doi: 10.1111/1346-8138.13306. Epub 2016 Feb 26.

PMID:
26919410
14.

Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis.

Ryoo JY, Yang HJ, Ji E, Yoo BK.

Ann Pharmacother. 2016 May;50(5):341-51. doi: 10.1177/1060028015626545. Epub 2016 Jan 18.

PMID:
26783352
15.

The safety of ustekinumab for the treatment of psoriatic arthritis.

López-Ferrer A, Laiz A, Puig L.

Expert Opin Drug Saf. 2017 Jun;16(6):733-742. doi: 10.1080/14740338.2017.1323864. Epub 2017 May 9. Review.

PMID:
28441904
16.

Safety of secukinumab in the treatment of psoriasis.

Blauvelt A.

Expert Opin Drug Saf. 2016 Oct;15(10):1413-20. doi: 10.1080/14740338.2016.1221923. Epub 2016 Aug 22. Review.

PMID:
27545070
17.

Secukinumab for rheumatology: development and its potential place in therapy.

Koenders MI, van den Berg WB.

Drug Des Devel Ther. 2016 Jun 24;10:2069-80. doi: 10.2147/DDDT.S105263. eCollection 2016. Review.

18.

Secukinumab: first global approval.

Sanford M, McKeage K.

Drugs. 2015 Feb;75(3):329-38. doi: 10.1007/s40265-015-0359-0. Review.

PMID:
25648267
19.

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.

Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S; FUTURE 1 Study Group.

N Engl J Med. 2015 Oct;373(14):1329-39. doi: 10.1056/NEJMoa1412679.

20.

Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.

Nakagawa H, Niiro H, Ootaki K; Japanese brodalumab study group.

J Dermatol Sci. 2016 Jan;81(1):44-52. doi: 10.1016/j.jdermsci.2015.10.009. Epub 2015 Oct 24.

PMID:
26547109

Supplemental Content

Support Center